AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

NYSTATIN BP

10 registrations across 3 African markets— 6 active

Markets with NYSTATIN BP

Recent registrations

Brand / ProductMarketHolderStatusExpires
Dawastin suspension
Suspension for Oral Use
🇿🇲ZambiaDawa LimitedactiveAug 2030
NYSTATIN TABLETS
Tablets
🇷🇼RwandaMERIT ORGANICS LTDactiveAug 2029
DAWASTIN ORAL SUSPENSION
Suspension
🇷🇼RwandaDAWA LIMITEDactiveAug 2029
GYNASTATIN BP
VAGINAL PESSARIES
🇷🇼RwandaBLISS GVS PHARMA LIMITEDactiveAug 2029
NYSKA-P
Suspension
🇷🇼RwandaS KANT HEALTHCARE LTDactiveAug 2029
MYCOREN SUSPENSION
SUSPENSION
🇷🇼RwandaRENE INDUSTRIES LTDactiveJul 2029
MYCONOVA 100 000IU/ML SUSPENSION
SUSPENSION
🇲🇼MalawiexpiredMar 2025
DAWASTIN 100 000IU SUSPENSION
SUSPENSION
🇲🇼MalawiexpiredMar 2025
NYSTATIN 100000 IU ORAL SUSPENSION
ORAL SUSPENSION
🇲🇼MalawiexpiredJun 2019
NYSTEC 100,000IU ORAL SUSPENSION
ORAL SUSPENSION
🇲🇼MalawiexpiredJun 2010

NYSTATIN BP in Africa — Regulatory Overview

NYSTATIN BP is registered across 3 African markets with 10 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Rwanda, Malawi, Zambia. AfricaRegulatory refreshes this data daily from official government sources.

Of the 10 registrations, 6 (60%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.